A Randomized, Blinded, Parallel Controlled, Phase III Clinical Trial to Evaluate Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above
Latest Information Update: 22 Jun 2020
At a glance
- Drugs Pneumococcal polysaccharide 23 valent vaccine Beijing Zhifei Lvzhu Biopharmaceutical (Primary)
- Indications Pneumococcal infections; Pneumonia
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Beijing Zhifei Lvzhu Biopharmaceutical
- 26 Feb 2020 New trial record